BACE1 and Alzheimer disease: As shown in the current work, CDCA reduced AlCl3-induced cognitive defects as assessed by Morris Water Maze and Y-maze tests, these results were paralleled by a diminution in the measured AD markers; viz., BACE1 and Aβ42.